Abstract
Leveraging its strong primary health-care system and universal health coverage backed by electronic data systems, well developed surveillance infrastructure, and high community demand, Israel has led a successful national rollout of Pfizer–BioNTech's BNT162b2 mRNA COVID-19 vaccine, achieving high population coverage at a rapid pace.1 The lessons learned from assessing the rollout have broad relevance. In the Lancet Respiratory Medicine, Yaniv Lustig and colleagues2 report the findings from their prospective, single-centre cohort study of 2607 nSARS-CoV-2 seronegative health-care workers in Israel (72·2% female, mean age 47·7 years [SD 12·5]) evaluated for their immune responses over 5 weeks following the first vaccine dose, including a timepoint 1–2 weeks after the second vaccine dose at week 3.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
